
Sosei Heptares has announced that it has dosed its first patient in its phase 1 trial evaluating HTL0048149 (HTL’149), a …
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
Alcami appoints Will Isom to lead laboratory services sales

